Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.96 |
| ▸ | ALPI | P09923 | 1/20 | 0.96 |
| ▸ | PKM | P14618 | 1/20 | 0.96 |
| ▸ | XIAP | P98170 | 1/20 | 0.96 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.67 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.67 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.58 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Phenylalanine SCHEMBL5288072 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL3117407 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL3117414 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL991789 | 1.00 | SLC7A5 (0.96) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL23159186 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL1449128 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL8835931 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1330932 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL288606 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Dl-Phenylalanine SCHEMBL1332173 | 0.98 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069206-B1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | ALESCO SRL (IT) | 2024-08-07 | — | — | EP | claimed |
| US-20230013586-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | PHARMANUTRA S.P.A. (IT) | 2023-01-19 | — | — | US | claimed |
| EP-4069206-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | Alesco S.r.l. (IT) | 2022-10-12 | — | — | EP | claimed |
| EP-4070801-A1 | COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS | Nutrition 21, LLC (US) | 2022-10-12 | — | — | EP | claimed |
| WO-2021111407-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | ALESCO S.R.L. (IT) | 2021-06-10 | — | — | WO | claimed |
| EP-3513790-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | JDS Therapeutics, LLC (US) | 2019-07-24 | — | — | EP | claimed |
| EP-2448412-B1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | JDS THERAPEUTICS LLC (US) | 2019-05-01 | — | — | EP | claimed |
| US-20150224140-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT | 2015-08-13 | — | — | US | claimed |
| EP-2012770-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Interhealth Nutraceuticals, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007121312-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | claimed |
| US-20250275982-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | ALESCO S.R.L. (IT) | 2025-09-04 | — | — | US | disclosed |
| EP-4069206-B1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | ALESCO SRL (IT) | 2024-08-07 | — | — | EP | disclosed |
| EP-4282281-A2 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | Alesco S.r.l. (IT) | 2023-11-29 | — | — | EP | disclosed |
| US-20230013586-A1 | SOLID FORM FORMULATION COMPRISING CHROMIUM OR COPPER OR A VITAMIN, COMPOSITIONS AND USES THEREOF | PHARMANUTRA S.P.A. (IT) | 2023-01-19 | — | — | US | disclosed |
| EP-4070801-A1 | COMPOSITIONS OF INSULIN AND CHROMIUM FOR THE TREATMENT AND PREVENTION OF DIABETES, HYPOGLYCEMIA AND RELATED DISORDERS | Nutrition 21, LLC (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2011002939-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | NUTRITION 21, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20090092560-A1 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| EP-2012770-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Interhealth Nutraceuticals, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121312-A9 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS INC (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007121312-A2 | TRIVALENT CHROMIUM COMPOUNDS, COMPOSITIONS AND METHODS OF USE | INTERHEALTH NUTRACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224140-A1 | CHROMIUM COMPLEXES AS ENHANCERS OF BRAIN GLUCOSE TRANSPORTERS | SLC2A3, SLC2A1, SLC2A2 | SLC7A5 336/4885PTGS1 3707/4885ALPI 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.